Overview

Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas

Status:
Active, not recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

The "NiTraSarc" trial evaluates the efficacy and feasibility (as determined by the safety and tolerability) of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas

Phase:

Phase 2

Details

Lead Sponsor:

University Medicine Greifswald

Collaborators:

Bristol-Myers Squibb
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
PharmaMar

Treatments:

Antibodies, Monoclonal
Nivolumab
Trabectedin